Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients
NCT03976544 · CRG UZ Brussel · PHASE4 · terminated · last registry update 2025-01-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “safety” | – | Registry record, CRG UZ Brussel |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ESR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-28Results posted on the registry: Canadian Cancer Trials Group, Ipatasertib + Fulvestrant (NCT04650581)
- 2026-01-23Results posted on the registry: Premier Research, 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR) (NCT00455156)
- 2026-01-22Results posted on the registry: Jennifer Lee Caswell-Jin, Alpelisib + Tamoxifen (NCT05101564)
- 2026-01-22Also stopped (terminated): Dana-Farber Cancer Institute, Neratinib + Fulvestrant (NCT03289039)
- 2026-01-09Results posted on the registry: The University of Texas Health Science Center, Houston, Estradiol + Placebo oral tablet (NCT04192266)
- 2026-01-09Also stopped (terminated): M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2026-01-05Also stopped (terminated): M.D. Anderson Cancer Center, Fulvestrant + Repotrectinib (NCT06408168)
- 2025-12-26Results posted on the registry: Estetra, Estetrol oral tablet + Placebo oral tablet (NCT04090957)
- 2025-12-19Results posted on the registry: University of Illinois Chicago, Estradiol Transdermal Patch 0.1 mg/24 hrs + Oral Micronized Progesterone 200mg (NCT04112368)
- 2025-12-09Results posted on the registry: Memorial Sloan Kettering Cancer Center, Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist (NCT00984399)
- 2025-12-08Results posted on the registry: Kimberly Myer, 10 µg/day E2 with NES 200® µg/day + 20 µg/day E2 with NES 200® µg/day (NCT01586000)
- 2025-12-05Results posted on the registry: National Institute of Mental Health (NIMH), Estradiol + Progesterone (NCT00001481)
- 2025-12-03Phase 3 first posted: TriHealth Inc., Estradiol 0.01% Vag Cream + testosterone 0.1% and estradiol 0.01% vaginal cream (NCT07260825)
- 2025-11-28Also stopped (terminated): Blueprint Medicines Corporation, BLU-222 + Carboplatin (NCT05252416)
- 2025-11-26Results posted on the registry: University of North Carolina, Chapel Hill, Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release + Placebo (NCT05388656)
- 2025-11-21Phase 3 first posted: Women's Cancer Study Group GmbH, Elacestrant + Standard-of-care endocrine treatment (NCT07242352)
- 2025-11-21Results posted on the registry: Organon and Co, NOMAC-E2 COC (NCT05264506)
- 2025-11-21Also stopped (terminated): Organon and Co, NOMAC-E2 COC (NCT05264506)
- 2025-10-27Results posted on the registry: AstraZeneca, Fulvestrant + Capivasertib (NCT04305496)
- 2025-10-03Phase 3 first posted: Risen (Suzhou) Pharma Tech Co., Ltd., JS105 + Dalpiciclib (NCT07207070)
- 2025-09-15Phase 3 first posted: Eli Lilly and Company, LY4064809 + Placebo (NCT07174336)
- 2025-08-03Phase 3 first posted: University of Michigan, Relugolix CT (NCT07100782)
- 2025-07-14Phase 3 first posted: Pfizer, PF-07248144 + Fulvestrant (NCT07062965)
- 2025-07-11Results posted on the registry: Eli Lilly and Company, Imlunestrant + Exemestane (NCT04975308)
- 2025-07-11Results posted on the registry: M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision